Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Empaveli
Pharma
Apellis' weak quarter could signal Syfovre 'nadir': analysts
Apellis' geographic atrophy med Syfovre may have hit a performance “nadir” in 2024’s third quarter, one group of analysts contends.
Fraiser Kansteiner
Nov 5, 2024 3:41pm
Novartis, Apellis roll out rival datasets in rare kidney disease
Oct 28, 2024 10:03am
Watch out, Novartis. Apellis scores major win in kidney diseases
Aug 8, 2024 2:28pm
Sobi boosts hematology sales with growth across key brands
Jul 16, 2024 1:27pm
Apellis bolsters case for Syfovre amid second-quarter earnings
Jul 31, 2023 9:58am
Apellis scraps pegcetacoplan development in ALS after trial flop
May 25, 2023 10:37am
